Double-Blind , Placebo-Controlled Randomized Phase II Study of Hangeshashinto for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving Chemotherapy (HANGESHA-C Study).
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2619737
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Oral administration of Hangeshashinto 7.5g/day t.i.d. after meals.
Oral administration of Placebo 7.5g/day t.i.d. after meals.
Primary outcome(s): Incidence of oral mucositis. grade>=2
Study Design: Parallel Randomized
创建时间：
2010-10-15
